Commentary
==========

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality \[[@B1]\] and critically ill patients are at a higher risk \[[@B2]\] of developing deep venous thrombosis (DVT) and pulmonary thromboembolism (PE) compared to non-critically ill patients. Low molecular weight heparin (LMWH) has shown superiority and is recommended over unfractionated heparin (UFH) in certain patient populations (such as trauma, spinal cord injury, and orthopedics \[[@B3]\]) but has not been well studied for general ICU patients. There have been four randomized studies of VTE prophylaxis in critically patients \[[@B4]-[@B7]\]. These studies showed decreased VTE with UFH and LMWH prophylaxis compared to placebo, but were underpowered to determine superiority of LMWH versus UFH. The PROTECT study was the largest study to date comparing LMWH to UFH prophylaxis in general ICU patients.

PROTECT was a multi-center, randomized, double blinded prospective trial which enrolled adult general intensive care unit (ICU) patients who were expected to have an ICU length of stay greater than 3 days. The primary endpoint was proximal lower extremity DVT detected on twice weekly screening ultrasound. Secondary endpoints included any DVT, PE, VTE, death, heparin-induced thrombocytopenia, major bleeding, and composite of death/VTE. The study was designed to detect a 30% relative risk reduction of proximal leg DVT in the dalteparin arm compared to the UFH arm assuming a control arm incidence of 9% \[[@B8]\]. The study failed to show a 30% relative risk reduction in rates of proximal leg DVT in the dalteparin (5.1%) group compared to the UFH (5.8%) group. The incidence of PE was 2.3% in the UFH group compared to 1.3% in the dalteparin group (hazard ratio, 0.51; 95% CI, 0.30 to 0.88; *P*= 0.01).

Strengths of this trial include multicenter recruitment, intention-to-treat analysis and randomized double blind design. The authors conducted a pilot trial of 128 patients \[[@B8]\] before commencing the main trial. Because of slow recruitment in the pilot trail, the authors trimmed PROTECT\'s exclusion criteria: they included all renal failure patients regardless of estimated glomerular filtration rate and included more patients with thrombocytopenia. These changes broadened the study group and made the PROTECT\'s results more generalizable.

Despite being a very large study, PROTECT may have needed more subjects to reveal a statistically significant reduction of DVTs. PROTECT\'s control arm event rate was less than the one used in the power calculation which may have underpowered the trial. The study failed to reject the primary null hypothesis and could not exclude a 32% benefit or a 23% harm associated with dalteparin versus UFH. Even though the incidence of DVT was similar in both arms, the study had a superiority design and therefore, we should not conclude non-inferiority between the two groups. The statistically significant reduction in incidence of PE must be taken with caution because this was a secondary endpoint and applying the results of a secondary endpoint to a general patient population has inherent uncertainty \[[@B9]\]. Furthermore, it is difficult to determine the clinical significance of a 1% reduction of PE without a reduced rate of proximal DVT or reduced mortality.

The PROTECT trial was negative for the primary endpoint of proximal DVT but does provide us with the best evidence to date regarding LMWH versus UFH for critically ill adults. No firm conclusions can be drawn from PROTECT even though there is a hint dalteparin might be superior to UFH (lower rates of PE and heparin-induced thrombocytopenia), but the data are just not robust enough to answer those questions.

Recommendation
==============

The PROTECT study is the best data to date comparing LMWH to UFH for primary prophylaxis of proximal leg DVT in critically ill adult patients. There is no conclusive evidence supporting the use of dalteparin in lieu of UFH; however, dalteparin appears to be a safe alternative to UFH for VTE prophylaxis in general ICU patients. We would recommend dalteparin over UFH if overall healthcare costs were similar or lower.
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